Results 131 to 140 of about 13,861 (164)
Some of the next articles are maybe not open access.
International Journal of Gynecological Cancer, 2007
Recurrent and advanced cervical cancers are associated with high mortality and a lack of effective treatment options, especially for women who are poor candidates for surgery or radiation therapy. The broad clinical effectiveness and manageable toxicity of topotecan in other human malignancies as well as promising recent study results suggest that it ...
S, Ackermann +3 more
openaire +2 more sources
Recurrent and advanced cervical cancers are associated with high mortality and a lack of effective treatment options, especially for women who are poor candidates for surgery or radiation therapy. The broad clinical effectiveness and manageable toxicity of topotecan in other human malignancies as well as promising recent study results suggest that it ...
S, Ackermann +3 more
openaire +2 more sources
Topotecan-induced Bronchiolitis
Southern Medical Journal, 2004Topotecan HCl is an antitumor drug exhibiting topoisomerase 1-inhibitory activity. Topotecan is used in the treatment of metastatic carcinoma of the ovary and as second-line treatment of small-cell lung cancer. Reported dose-limiting adverse reactions to topotecan are primarily hematologic in nature.
Colin C, Edgerton +2 more
openaire +2 more sources
Activity of topotecan in retinoblastoma
Ophthalmic Genetics, 2004To report our experience with topotecan in children with relapsed/refractory metastatic and intraocular retinoblastoma.Topotecan was administered intravenously as a 30-min infusion at a dose of 2 mg/m2/d for five consecutive days and repeated after three weeks.
Guillermo L, Chantada +5 more
openaire +2 more sources
Topotecan (Hycamptin) and Topotecan‐Containing Regimens in the Treatment of Hematologic Malignancies
Annals of the New York Academy of Sciences, 2000Abstract: Single‐agent topotecan is an active drug in chemotherapy‐naive MDS and CMML and, to a lesser degree, in refractory/relapsed acute leukemias, low‐/intermediate‐grade lymphoma, and myeloma. Its combination with cytosine arabinoside induces complete remissions in high‐risk MDS/CMML.
M, Beran, H M, Kantarjian
openaire +2 more sources